Volume : 09, Issue : 08, August – 2022
Title:
52.PHARMACOLOGICAL TREATMENT OF HYPERTENSION AND SIDE EFFECTS
Authors :
Fatimah Abdullah Abu Abdullah, Zahra Ali Abu Alrehi , Zahra Hussain Suhail, Suad Abdullah Al-Nasser, Fatimah Ali Alawami, Asma Naji Al Huwaidi, Fatimah Abbas Al Jaroodi, Amal Ali AlDhamen, Jalila Salman Al Shurfa, Amira Abdullah Alabbad, Nora Abdrubalameer Shaabann, Zainab Saleh Almadeh, Laila Abdullah Almhaysen, Abeer Hassan Al Khamis, Roqaiah Ali Almarhoun
Abstract :
The treatment of hypertension involves various classes of medications, each associated with specific side effects. Common antihypertensive agents include ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, diuretics, and others, which can lead to adverse effects. This review highlighted the significance of using antihypertension medication and how it reduces the cardiovascular risks and side effects of discontinued therapy, indicating a critical balance between benefits and adverse events. Antihypertensive treatments are effective, their side effects can significantly impact patient adherence and quality of life.
Keywords: Hypertension, pharmacological treatment, Side effect
Cite This Article:
Please cite this article in press Fatimah Abdullah Abu Abdullah et al Pharmacological Treatment Of Hypertension And Side Effects., Indo Am. J. P. Sci, 2022; 09(8).
,
Number of Downloads : 10
References:
1. Deepika RM, Ravisankar P, Priya JD, Surekha P. Cardiovascular Disease Death Rate-Current Scenario in The State of Andhra Pradesh.
2. Kaur R, Khanna NJSD. Pathophysiology and risk factors related to hypertension and its cure using herbal drugs. 2012;2(4):245-56.
3. Kokubo Y, Iwashima Y, Kamide KJP, Disease PoC. Hypertension: Introduction, types, causes, and complications. 2015:635-53.
4. Schellack N, Naicker PJSPJ. Hypertension: a review of antihypertensive medication, past and present. 2015;82(2):17-25.
5. Kumar B, Jyothi K, Sravya N, Rajveersingh R, Swamy M, Sowmya Mathew SM. Evaluation of risk factors in hypertension patients visiting to rural tertiary care teaching hospital. 2012.
6. Knieć M, Kujawska-Łuczak M, editors. Wpływ stylu życia na występowanie nadciśnienia tętniczego u dorosłych. Forum Zaburzeń Metabolicznych; 2012.
7. Оyunbileg DJJoG, Protection E. Environmental and occupational risk factors effect to arterial hypertension: correlation between arterial hypertension and lead. 2015;3(02):60.
8. Blum AJAJoP, Toxicology. The “Forgotten Side Effect” of Thiazides. 2009;4(4):174-6.
9. Eladari D, Chambrey RJJoN. Identification of a novel target of thiazide diuretics. 2011;24(4):391-4.
10. Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born B-JHJH. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. 2015;65(5):1033-40.
11. Merwe W, Cicovic S, van der Merwe VJJH. Thiazide Intolerance-A New Zealand Perspective. 2014;3(136):2167-1095.1000136.
12. Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi GJDc. Diuretic treatment of hypertension. 2011;34(Suppl 2):S313.
13. Karadsheh F, R Weir MJCHR. The use of thiazides in chronic kidney disease. 2014;10(2):81-5.
14. Morisco C, Trimarco BJA, Hypertension Ai, Failure H. Angiotensin-converting enzyme inhibitors and at1 antagonists for the treatment of hypertension. 2015:1-39.
15. Divya S, Bhavya N, Kumar KP, Keerthi KS, Dhanaraju MJWJoMS. New Era of Antihypertensive Agents-Vasopeptidase Inhibitors. 2011;6(4):193-201.
16. Ibrahim MMJJoHH. RAS inhibition in hypertension. 2006;20(2):101-8.
17. Catanzaro DF, Frishman WHJSmj. Angiotensin receptor blockers for management of hypertension. 2010;103(7):669-73.
18. Andreadis EAJHC. Angiotensin II-Receptor Blockers: their Relevance in Clinical Practice. 2010;5(1).
19. Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi GJHR. Angiotensin receptor blockers in hypertension. New insights from Japan. 2010;33(5):394-7.
20. Saha SAJSMJ. Angiotensin-receptor blockers for the management of hypertension: new insights, new challenges. 2010;103(7):599-600.
21. Bawazir LAA, Sianipar WJGCS, Practice. Treating patients with hypertension in Indonesia’s primary health care centre: A challenging condition. 2019;2019(2).
22. J Caballero-Gonzalez FJC, Chemistry HAiM. Calcium channel blockers in the management of hypertension in the elderly. 2014;12(3):160-5.
23. Safar M, Blacher JJAJoCD. Thiazide-like/calcium channel blocker agents: a major combination for hypertension management. 2014;14:423-32.
24. Kanno Y, Ohno Y, Takenaka TJP, Disease PoC. Calcium Channel Blockers in the Treatment of Hypertension. 2015:807-22.
25. Coca A, Mazón P, Aranda P, Redón J, Divisón JA, Martínez J, et al. Role of dihydropyridinic calcium channel blockers in the management of hypertension. 2013;11(1):91-105.
26. Akbar S, Alorainy MSJSmj. The current status of beta blockers’ use in the management of hypertension. 2014;35(11):1307.
27. Tomlinson B, Dalal J, Huang J, Low L, Park C, Rahman A, et al. The role of β-blockers in the management of hypertension: an Asian perspective. 2011;27(5):1021-33.
28. Cruickshank JJJ. β-Blocker Therapy for Patients With Hypertension. 2014;311(8):862-.
29. Ker JAJSAFP. Beta blockers and their combinations in the management of hypertension. 2012;54(5).
30. Hargovan M, Ferro AJJcd. Aldosterone synthase inhibitors in hypertension: current status and future possibilities. 2014;3:2048004014522440.
31. Colussi G, Catena C, Sechi LAJJoh. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. 2013;31(1):3-15.
32. Costa MB, Ezequiel DGA, Lovis JCM, Oliveira MM, de Paula RBJTJoCH. Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome. 2010;12(9):753.
33. Chapman N, Chen C-Y, Fujita T, Hobbs FR, Kim S-J, Staessen JA, et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? 2010;28(9):1796-803.
34. Houston MC. Alpha1-blocker combination therapy for hypertension. Postgraduate Medicine. 1998;104(3):167-87.
35. Panchanatham M, Shah SNJTJotAoPoI. Overview of alpha-blockers in hypertension: reappraisal of perspectives. 2014. p. 5-8.
36. Taylor AA, Pool JLJAJoT. Clinical role of direct renin inhibition in hypertension. 2012;19(3):204-10.
37. Jadhav M, Yeola C, Zope G, Nabar AJJoPM. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. 2012;58(1):32-8.
38. Cohn JN, McInnes GT, Shepherd AM. Direct-Acting Vasodilators. 2011;13(9):690-2.
39. Sica DA, Gehr TWJTJoCH. Direct vasodilators and their role in hypertension management: minoxidil. 2001;3(2):110-4.